Completed PHASE3 INTERVENTIONAL NCT00003577

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

National Breast Cancer Study of Epirubicin + CMF v Classical CMF Adjuvant Therapy

Sponsor: University Hospital Birmingham

Interventions CMF regimen adjuvant therapy cyclophosphamide epirubicin hydrochloride fluorouracil methotrexate radiation therapy

Updated 5 times since 2017 Last updated: Dec 18, 2013 Started: Mar 31, 1996 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by University Hospital Birmingham and has accumulated 5 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Birmingham

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United Kingdom